Roche Gets European Approval for Tecentriq Combo Therapy Against Lung Cancer
The European Commission approved Roche's Tecentriq plus Avastin and chemo as a first treatment for certain lung cancer patients.
Roche announced on Friday that the European Commission has approved its drug Tecentriq in combination with Avastin and chemotherapy as an initial treatment for people with a specific type of lung cancer. The approval provides a new first-line option for patients in Europe, based on the company's announcement. Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/GVcNj3yx2u4/roche-gets-european-approval-for-tecentriq-combo-vs-lung-cancer-idUSKCN1QP0JJ Note: This is regulatory approval news rather than a new peer-reviewed study with reported sample size or trial design details.
VITALIS: For ordinary people facing this type of lung cancer, it means another proven treatment combo could become available sooner in Europe, potentially helping patients live longer with better options right after diagnosis.
Sources (1)
- [1]Roche gets European approval for Tecentriq combo vs. lung cancer(http://feeds.reuters.com/~r/reuters/healthNews/~3/GVcNj3yx2u4/roche-gets-european-approval-for-tecentriq-combo-vs-lung-cancer-idUSKCN1QP0JJ)